$500.3 Million

Evotec SE

Initial Public Offering

Bookrunner, November 2021

Evotec SE (“Evotec” or the “Company”) is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. The Company has built a comprehensive suite of fully integrated, next-generation technology platforms, including EVOiR&D, EVOpanOmics, EVOpanHunter, the iPSC drug discovery platform and EVOaccess. By leveraging these platforms, the Company is able to provide solutions to its partners that enable significant improvements in the quality of new drugs while accelerating the drug discovery process and reducing the high cost of attrition often associated with the traditional drug discovery process.

More Like This

Mar 2022
$79.4 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Nov 2021
$116.3 Million

Initial Public Offering

Bookrunner

View Details
Oct 2021
$86.9 Million

Initial Public Offering

Lead Left Bookrunner

View Details